Clinical journal of the American Society of Nephrology : CJASN
-
Clin J Am Soc Nephrol · Mar 2009
Multicenter StudyEpoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.
Intrapatient variability of hemoglobin (Hb) is a newly proposed determinant of adverse outcome in chronic kidney disease (CKD). We evaluated whether intensity of epoetin therapy affects Hb variability and renal survival in nondialysis CKD. ⋯ Lack of adjustment of EPO worsens Hb variability in CKD. Hb variability may be associated with renal survival, but further studies are needed to explore the association versus causal relationship.